Search results
Results from the WOW.Com Content Network
ASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe.
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology. For more information on these guidelines, including information about planned guidelines, please access the ASCO.org guidelines page. Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care.
The purpose of this guideline is to provide expert guidance on the systemic treatment of metastatic breast cancer (MBC) to clinicians, public health leaders, patients, and policymakers in resource-constrained settings.
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended care options.
This clinical practice guideline addresses five key areas of breast cancer survivorship to provide recommendations on best practice in the management of adult women after breast cancer treatment, focusing on the role of primary care clinicians and other clinicians who care for post-treatment breast cancer survivors. The five areas covered include:
american cancer society/american society of clinical oncology breast cancer survivorship care guideline Clinical Domain Recommendation Level of Evidence Surveillance for Breast Cancer Recurrence
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update These adjuvant chemotherapy regimens can be used for patients with early breast cancer:
Patients with early-stage HER2-negative breast cancer with pathologic invasive residual disease at surgery following standard anthracycline and taxane-based preoperative therapy may be offered up to 6-8 cycles of adjuvant capecitabine.
In 2016, ASCO endorsed the use of genomic tests (Oncotype Dx, MammaPrint, Prosigna, EndoPredict, Breast Cancer Index [BCI]) in patients with early-stage breast cancer to guide decisions of adjuvant endocrine and chemotherapy.
ABSTRACT. PURPOSE To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting–guideline recommended treatment is unavailable.